Bao Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bao Zhu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Kejing Shao
Department of Nuclear Medicine
4 shared publications- Mengjun Jiang
Affiliated Wuxi People’s Hospital
4 shared publications - Biao Huang
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
2 shared publications Fei Chen
Department of Nuclear Medicine, Nanjing Medical University Affiliated Wuxi People's Hospital, Wuxi, Jiangsu, P. R. China
2 shared publications- Fei Chen
Department of Nuclear Medicine
2 shared publications Qinyue Gao
Department of Nuclear Medicine, the Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (6) , 1043-1054
FAPI Dimerization for Theranostic Applications: Molecular Design, Preclinical Validation, and Clinical Translation
Fibroblast activation protein (FAP), a serine protease overexpressed in cancer-associated fibroblasts of >90% epithelial malignancies, has emerged as a highly promising pan-cancer target for theranostic radiopharmaceuticals. However, the rapid clearance of monomeric FAP inhibitors (FAPIs) limits their therapeutic efficacy despite excellent diagnostic performance. Multimerization strategies-particularly dimeric and heterodimeric constructs-have been developed to overcome this limitation through enhanced binding avidity and prolonged tumor retention. This review provides a comprehensive analysis of recent advances in FAPI-based multimers, focusing on their molecular design, chemical synthesis, preclinical evaluation, and early clinical applications. We examine the role of linker chemistry (length, flexibility, cleavability) and chelator selection in optimizing pharmacokinetics and tumor-to-background contrast. Key examples include homodimers (e.g., DOTA-2P(FAPI)2, BiOncoFAP) that leverage the polyvalency effect, and heterodimers (e.g., FAPI-RGD, PSFA-01) that enable dual-targeting of FAP and complementary receptors such as integrin αvβ3 or PSMA. These probes show superior tumor uptake and retention in preclinical models and have demonstrated enhanced diagnostic sensitivity and therapeutic potential in clinical trials across multiple cancer types. Beyond oncology, emerging applications in fibrotic and inflammatory diseases-such as rheumatoid arthritis and interstitial lung disease-highlight the versatile utility of FAPI multimers. While challenges including renal uptake, synthetic complexity, and cost remain, ongoing innovations in chemical design and combination therapies position these agents as transformative tools in precision theranostics, bridging high-contrast imaging with effective radioligand therapy for personalized patient management.
- 24 February 2026
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (6) , 1043-1054
Open AccessFAPI Dimerization for Theranostic Applications: Molecular Design, Preclinical Validation, and Clinical Translation
Fibroblast activation protein (FAP), a serine protease overexpressed in cancer-associated fibroblasts of >90% epithelial malignancies, has emerged as a highly promising pan-cancer target for theranostic radiopharmaceuticals. However, the rapid clearance of monomeric FAP inhibitors (FAPIs) limits their therapeutic efficacy despite excellent diagnostic performance. Multimerization strategies-particularly dimeric and heterodimeric constructs-have been developed to overcome this limitation through enhanced binding avidity and prolonged tumor retention. This review provides a comprehensive analysis of recent advances in FAPI-based multimers, focusing on their molecular design, chemical synthesis, preclinical evaluation, and early clinical applications. We examine the role of linker chemistry (length, flexibility, cleavability) and chelator selection in optimizing pharmacokinetics and tumor-to-background contrast. Key examples include homodimers (e.g., DOTA-2P(FAPI)2, BiOncoFAP) that leverage the polyvalency effect, and heterodimers (e.g., FAPI-RGD, PSFA-01) that enable dual-targeting of FAP and complementary receptors such as integrin αvβ3 or PSMA. These probes show superior tumor uptake and retention in preclinical models and have demonstrated enhanced diagnostic sensitivity and therapeutic potential in clinical trials across multiple cancer types. Beyond oncology, emerging applications in fibrotic and inflammatory diseases-such as rheumatoid arthritis and interstitial lung disease-highlight the versatile utility of FAPI multimers. While challenges including renal uptake, synthetic complexity, and cost remain, ongoing innovations in chemical design and combination therapies position these agents as transformative tools in precision theranostics, bridging high-contrast imaging with effective radioligand therapy for personalized patient management.
- 29 March 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Mechanics in Medicine and Biology
- Vol. 25 (02)
BONE METASTASIS CLASSIFICATION BASED ON FEDERATED LEARNING FOR SPECT WHOLE-BODY BONE SCANNING
Early detection of bone metastasis is important, given its severe impact on patients’ quality of life. A dataset containing 977 annotated whole-body bone scan (WBS) images from diverse sources was constructed. An innovative framework combining federated learning (FL) based on the residual convolutional neural network was adopted, and the rectified linear unit (ReLU) in ResNet was replaced with LeakyReLU to optimize the network. The experiments were carried out from two aspects: FL and residual network. Compared with various models, the results show that the FedAvg model has excellent performance while protecting privacy, and the improved ResNet algorithm has an accuracy exceeding 95% in the bone metastasis classification task. The experiment indicates that this framework can enhance the efficiency and accuracy of bone metastasis diagnosis, protect privacy, and lay a foundation for clinical applications.
- 29 March 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Mechanics in Medicine and Biology
- Vol. 25 (02)
BONE METASTASIS CLASSIFICATION BASED ON FEDERATED LEARNING FOR SPECT WHOLE-BODY BONE SCANNING
Early detection of bone metastasis is important, given its severe impact on patients’ quality of life. A dataset containing 977 annotated whole-body bone scan (WBS) images from diverse sources was constructed. An innovative framework combining federated learning (FL) based on the residual convolutional neural network was adopted, and the rectified linear unit (ReLU) in ResNet was replaced with LeakyReLU to optimize the network. The experiments were carried out from two aspects: FL and residual network. Compared with various models, the results show that the FedAvg model has excellent performance while protecting privacy, and the improved ResNet algorithm has an accuracy exceeding 95% in the bone metastasis classification task. The experiment indicates that this framework can enhance the efficiency and accuracy of bone metastasis diagnosis, protect privacy, and lay a foundation for clinical applications.
- 19 March 2025
- Published by Elsevier in Analytical Biochemistry
- Vol. 702, 115848
Establishment of GDF15 time-resolved fluorescence immunoassay and its clinical application in colorectal cancer
- 19 March 2025
- Published by Elsevier in Analytical Biochemistry
- Vol. 702, 115848
Establishment of GDF15 time-resolved fluorescence immunoassay and its clinical application in colorectal cancer
- 18 March 2025
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 334 (4) , 2557-2566
Advances in PET imaging of fibroblast activating protein inhibitors for the diagnosis of common malignant tumors
- 18 March 2025
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 334 (4) , 2557-2566
Advances in PET imaging of fibroblast activating protein inhibitors for the diagnosis of common malignant tumors
- 7 January 2025
- Published by Springer Nature in Journal of Fluorescence
- Vol. 35 (8) , 7413-7421
Establishment of Time-Resolved Fluorescence Immunoassay for Thyrotropin Receptor Antibodies and Clinical Application
Thyroid-stimulating hormone receptor antibody (TRAb) is a specific marker for Graves’ disease (GD) and the measurement of which can improve the accuracy of GD diagnosis. Current detection methods utilize porcine-derived polyclonal-TRAb, which is unstable and is a source of significant inter-assay variability. This study aims to establish a time-resolved fluorescence immunoassay (TRFIA) method based on stable source of recombinant human TSHR and TRAb for the detection of serum TRAb. The neutralization inhibition method was used in this study. The specific binding of goat-anti-mouse IgG and chimeric construct Fc fragment human TSHR were immobilized on the microplate, and serum TRAb was detected by the competition between Eu3+-labeled human TRAb and the serum TRAb. The TRAb-TRFIA has a wide linear range (0.081–50 IU/L). The intra-assay precision was 2.17–5.41% (< 10%), and the inter-assay precision was 5.75–9.58% (< 15%). No cross-reactivity was observed between TRAb and recombinant human IgG1, IgG2, IgG3, or IgG4. The recovery rate was 106.37%. The TRAb–TRFIA method was significantly correlated with the Roche chemiluminescence method (R2 = 0.9130). TRFIA based on recombinant human TSHR and TRAb with high stability, strong specificity, high sensitivity and wide linear range was established for the detection of TRAb, which can be used for clinical detection.
- 7 January 2025
- Published by Springer Nature in Journal of Fluorescence
- Vol. 35 (8) , 7413-7421
Establishment of Time-Resolved Fluorescence Immunoassay for Thyrotropin Receptor Antibodies and Clinical Application
Thyroid-stimulating hormone receptor antibody (TRAb) is a specific marker for Graves’ disease (GD) and the measurement of which can improve the accuracy of GD diagnosis. Current detection methods utilize porcine-derived polyclonal-TRAb, which is unstable and is a source of significant inter-assay variability. This study aims to establish a time-resolved fluorescence immunoassay (TRFIA) method based on stable source of recombinant human TSHR and TRAb for the detection of serum TRAb. The neutralization inhibition method was used in this study. The specific binding of goat-anti-mouse IgG and chimeric construct Fc fragment human TSHR were immobilized on the microplate, and serum TRAb was detected by the competition between Eu3+-labeled human TRAb and the serum TRAb. The TRAb-TRFIA has a wide linear range (0.081–50 IU/L). The intra-assay precision was 2.17–5.41% (< 10%), and the inter-assay precision was 5.75–9.58% (< 15%). No cross-reactivity was observed between TRAb and recombinant human IgG1, IgG2, IgG3, or IgG4. The recovery rate was 106.37%. The TRAb–TRFIA method was significantly correlated with the Roche chemiluminescence method (R2 = 0.9130). TRFIA based on recombinant human TSHR and TRAb with high stability, strong specificity, high sensitivity and wide linear range was established for the detection of TRAb, which can be used for clinical detection.
- 20 February 2024
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 333 (4) , 2059-2068
Evaluation of 18F-AlF-labeled IF7 dimer as a promising molecular probe for tumor targeting PET imaging in mice
- 20 February 2024
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 333 (4) , 2059-2068
Evaluation of 18F-AlF-labeled IF7 dimer as a promising molecular probe for tumor targeting PET imaging in mice
- 29 April 2023
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 332 (6) , 1625-1645
Multimodal radiolabeled gold nanoparticle molecular probes: synthesis, imaging, and applications
- 29 April 2023
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 332 (6) , 1625-1645
Multimodal radiolabeled gold nanoparticle molecular probes: synthesis, imaging, and applications
- 20 June 2020
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 63 (12) , 494-501
Positron emission tomography imaging of a novel Anxa1‐targeted peptide 18F‐Al‐NODA‐Bn‐p‐SCN‐GGGRDN‐IF7 in A431 cancer mouse models
Annexin 1 (Anxa1) is a highly specific surface marker of tumor vasculature in the lung and prostate solid tumors. The IF7 peptide was modified with a hydrophilic linker, GGGRDN, and coupled with a new bifunctional chelating agent NODA‐Bn‐p‐SCN. The resulting peptides (NODA‐Bn‐p‐SCN‐GGGRDN‐IF7) were successfully labeled with Al18F. The targeting characteristics of the radiolabeled peptides were evaluated in the Anxa1 positive A431 tumor model. Micro‐positron emission tomography (micro‐PET) imaging revealed that the A431 tumors were clearly visualized (5.74 ± 1.13%ID/g, 3.92 ± 0.78%ID/g and 1.30 ± 0.43%ID/g at 0.5, 1, and 2 h post‐injection, respectively). Anxa1 binding specificity was also demonstrated by reduced tumor uptake after co‐injection with excessive unlabeled GGGRDN‐IF7 peptide at 30, 60, and 120 min post‐injection. 18F‐Al‐NODA‐Bn‐p‐SCN‐GGGRDN‐IF7 might be a potential PET imaging agent for detecting Anxa1 levels in cancers due to the favorable characteristics such as convenient synthesis, specific Anxa1 targeting, and good tumor uptakes.
- 20 June 2020
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 63 (12) , 494-501
Positron emission tomography imaging of a novel Anxa1‐targeted peptide 18F‐Al‐NODA‐Bn‐p‐SCN‐GGGRDN‐IF7 in A431 cancer mouse models
Annexin 1 (Anxa1) is a highly specific surface marker of tumor vasculature in the lung and prostate solid tumors. The IF7 peptide was modified with a hydrophilic linker, GGGRDN, and coupled with a new bifunctional chelating agent NODA‐Bn‐p‐SCN. The resulting peptides (NODA‐Bn‐p‐SCN‐GGGRDN‐IF7) were successfully labeled with Al18F. The targeting characteristics of the radiolabeled peptides were evaluated in the Anxa1 positive A431 tumor model. Micro‐positron emission tomography (micro‐PET) imaging revealed that the A431 tumors were clearly visualized (5.74 ± 1.13%ID/g, 3.92 ± 0.78%ID/g and 1.30 ± 0.43%ID/g at 0.5, 1, and 2 h post‐injection, respectively). Anxa1 binding specificity was also demonstrated by reduced tumor uptake after co‐injection with excessive unlabeled GGGRDN‐IF7 peptide at 30, 60, and 120 min post‐injection. 18F‐Al‐NODA‐Bn‐p‐SCN‐GGGRDN‐IF7 might be a potential PET imaging agent for detecting Anxa1 levels in cancers due to the favorable characteristics such as convenient synthesis, specific Anxa1 targeting, and good tumor uptakes.
- 4 April 2019
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 320 (2) , 525-530
Preparation and SPECT imaging of the novel Anxa 1-targeted probe 99mTc-p-SCN-Bn-DTPA-GGGRDN-IF7
- 4 April 2019
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 320 (2) , 525-530
Preparation and SPECT imaging of the novel Anxa 1-targeted probe 99mTc-p-SCN-Bn-DTPA-GGGRDN-IF7
- 1 May 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (10) , 2547-2550
Synthesis and biological assessment of folate-accepted developer 99mTc-DTPA-folate-polymer
- 1 May 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (10) , 2547-2550
Synthesis and biological assessment of folate-accepted developer 99mTc-DTPA-folate-polymer